From a query of 385 adult ALL patients with at least one banked specimen, clinical abstraction revealed 50.6% (195) to have received an asparaginase treatment, of which 35.3% (69) exhibited some level of adverse reaction with 20% (25) experiencing acute onset of illness involving skin and mucosal tissue or respiratory compromise. Here, ASPG is linked to acute lymphoblastic leukemia.